Clinical and Genomic Features of Patients with Renal Cell Carcinoma and Advanced Chronic Kidney Disease: Analysis of a Multi-Institutional Database.

BAP1 chronic kidney disease genomics mutation renal cell carcinoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
18 May 2024
Historique:
received: 22 04 2024
revised: 30 04 2024
accepted: 16 05 2024
medline: 25 5 2024
pubmed: 25 5 2024
entrez: 25 5 2024
Statut: epublish

Résumé

Patients with advanced chronic kidney disease (ACKD) are at an increased risk of developing renal cell carcinoma (RCC), but molecular alterations in RCC specimens arising from ACKD and overall survival (OS) in affected patients are not well defined. Using the Oncology Research Information Exchange Network (ORIEN) Total Cancer Care Of 296 patients with RCC, 61 met the criteria for ACKD. The most common somatic mutations in the overall cohort were in Using the clinicogenomic ORIEN database, our study found lower rates of

Sections du résumé

BACKGROUND BACKGROUND
Patients with advanced chronic kidney disease (ACKD) are at an increased risk of developing renal cell carcinoma (RCC), but molecular alterations in RCC specimens arising from ACKD and overall survival (OS) in affected patients are not well defined.
PATIENTS AND METHODS METHODS
Using the Oncology Research Information Exchange Network (ORIEN) Total Cancer Care
RESULTS RESULTS
Of 296 patients with RCC, 61 met the criteria for ACKD. The most common somatic mutations in the overall cohort were in
CONCLUSIONS CONCLUSIONS
Using the clinicogenomic ORIEN database, our study found lower rates of

Identifiants

pubmed: 38791999
pii: cancers16101920
doi: 10.3390/cancers16101920
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : University of Colorado Cancer Center
ID : P30CA046934

Auteurs

Corbin J Eule (CJ)

Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

Junxiao Hu (J)

Biostatistics Core, University of Colorado Cancer Center, Aurora, CO 80045, USA.

Dale Hedges (D)

Aster Insights, Hudson, NY 13610, USA.

Alkesh Jani (A)

Division of Nephrology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

Thomas Pshak (T)

Division of Urology, Department of Surgery, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

Brandon J Manley (BJ)

Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.

Alejandro Sanchez (A)

Division of Urology, Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.

Robert Dreicer (R)

Division of Medical Oncology, Department of Medicine, University of Virginia Comprehensive Cancer Center, Charlottesville, VA 22908, USA.

Zin W Myint (ZW)

Division of Medical Oncology, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY 40506, USA.

Yousef Zakharia (Y)

Division of Hematology, Oncology, and Blood and Bone Marrow Transplantation, Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.

Elaine T Lam (ET)

Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.

Classifications MeSH